doi: 10.1016/s0003-4266(06)72569-0.
Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG)
Affiliations
- PMID: 16639364
- DOI: 10.1016/s0003-4266(06)72569-0
Item in Clipboard
Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG)
Ann Endocrinol (Paris).
2006 Apr.
No abstract available
Similar articles
-
Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.JAMA. 2004 Jul 28;292(4):490-5. doi: 10.1001/jama.292.4.490. JAMA. 2004. PMID: 15280347 Review.
-
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.Curr Opin Pharmacol. 2005 Dec;5(6):618-25. doi: 10.1016/j.coph.2005.06.005. Epub 2005 Sep 26. Curr Opin Pharmacol. 2005. PMID: 16188502 Review.
-
Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.J Cell Biochem. 2006 Feb 1;97(2):226-32. doi: 10.1002/jcb.20674. J Cell Biochem. 2006. PMID: 16240334 Review.
-
[Osteoprotegerin--a neutralizing receptor, protector of bones and a potential antiresorptive agent].Med Pregl. 2005 Jul-Aug;58(7-8):362-7. doi: 10.2298/mpns0508362a. Med Pregl. 2005. PMID: 16296579 Review. Serbian.
-
Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.Medscape Womens Health. 2000 Mar;5(2):5. Medscape Womens Health. 2000. PMID: 10792853 Review.
Cited by
-
[Rheumatism and bone metabolism].Orthopade. 2019 Nov;48(11):911-916. doi: 10.1007/s00132-019-03809-3. Orthopade. 2019. PMID: 31531702 Review. German.
-
Osteoporosis in celiac disease and in endocrine and reproductive disorders.World J Gastroenterol. 2008 Jan 28;14(4):498-505. doi: 10.3748/wjg.14.498. World J Gastroenterol. 2008. PMID: 18203279 Free PMC article. Review.
-
Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection.AIDS Rev. 2014 Jul-Sep;16(3):123-33. AIDS Rev. 2014. PMID: 25102334 Free PMC article. Review.
-
Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists.Ann Rheum Dis. 2007 Dec;66(12):1675-8. doi: 10.1136/ard.2007.071910. Epub 2007 Jul 31. Ann Rheum Dis. 2007. PMID: 17666448 Free PMC article.
-
Increased calcification in osteoprotegerin-deficient smooth muscle cells: Dependence on receptor activator of NF-κB ligand and interleukin 6.J Vasc Res. 2014;51(2):118-31. doi: 10.1159/000358920. Epub 2014 Mar 7. J Vasc Res. 2014. PMID: 24642764 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
